## 1. <u>Cyclophosphamide</u>

Drug Class:

• Alkylating agent (Nitrogen mustard derivative)

Mechanism of Action:

- Prodrug activated by liver microsomal enzymes into:
- 4-hydroxycyclophosphamide and Aldophosphamide
- Aldophosphamide → nonenzymatically converted into:
- Phosphoramide mustard (cytotoxic: crosslinks DNA) and Acrolein
- Acrolein (toxic metabolite  $\rightarrow$  bladder toxicity)

Therapeutic Uses:

• Breast cancer. •Ovarian cancer • Wilms' tumor •Others (e.g., lymphomas)

Adverse Effects:

(All are dose-related, especially in rapidly dividing tissues)

- 1. Nausea and vomiting
- 2. Vesicant effects  $\rightarrow$  local tissue damage at injection site
- 3. Hemorrhagic cystitis
- Due to acrolein
- Prevented by hydration
- 4. Carcinogenic potential → risk of secondary AML (acute myelogenous leukemia)
- 5. Bone marrow suppression
- Leukopenia
- Thrombocytopenia
- Bleeding
- 6. Alopecia

### 2. <u>Methotrexate (MTX</u>)

Drug Class:

Antimetabolite, Folic acid analog

Mechanism of Action:

- Inhibits dihydrofolate reductase (DHFR)  $\rightarrow \downarrow$  tetrahydrofolate (THF)  $\rightarrow \downarrow$  synthesis of:
- Thymidylate (dTMP)
- Purine nucleotides
- Amino acids (serine, methionine)
- Disrupts DNA, RNA, and protein synthesis

Polyglutamate Activation:

- Converted intracellularly into MTX polyglutamates by folylpolyglutamate synthase.
- Polyglutamates are selectively retained in tumor cells for enhanced effect.

Resistance Mechanisms:

- 1. ↓ MTX transport via folate carriers/receptors
- 2. ↓ MTX polyglutamate formation
- 3. ↑ DHFR enzyme levels (gene amplification)
- 4. Altered DHFR with reduced MTX affinity
- 5. Efflux via P170-glycoprotein (MDR transporter)

Routes of Administration:

• Oral, IV, Intrathecal

Elimination:

- Renal (active transport)
- Dose adjustment needed in renal dysfunction
- Renal clearance is decreased by:
- Aspirin
- NSAIDs
- Penicillins
- Cephalosporins

## Leucovorin Rescue:

- · Leucovorin (5-formyltetrahydrofolate) reverses toxic effects
- Used in:
- High-dose MTX therapy
- Accidental overdose

Therapeutic Uses:

- Breast cancer
- Bladder cancer
- Choriocarcinoma
- Others (e.g., leukemia, lymphoma)

## Toxicity:

- 1. Mucositis, diarrhea
- 2. Hepatotoxicity
- 3. Myelosuppression (neutropenia, thrombocytopenia)
- 4. Neurotoxicity: cognitive changes
- 5. Immunoallergic pneumonitis  $\rightarrow$  can lead to pulmonary fibrosis
- 6. Chemical pneumonitis
- 7. Renal dysfunction

## <u>1. Doxorubicin (Anthracycline Anticancer Antibiotic)</u>

## Section Mechanism of Action

- 1. Inhibits topoisomerase II
- 2. Intercalates into DNA  $\rightarrow$  blocks replication and transcription.
- 3. Generates free radicals (semiquinone & oxygen species, iron-dependent)  $\rightarrow$  cardiotoxicity.
- 4. Binds cellular membranes  $\rightarrow$  alters fluidity and ion transport.

## Pharmacokinetics

- Route: IV only.
- Metabolism: Liver (extensive).
- Excretion: ~50% in bile.
- Dose adjustment required in: Hepatic dysfunction.

## Therapeutic Uses

- 1. Breast cancer
- 2. Endometrial cancer
- 3. Ovarian cancer
- 4. Testicular cancer
- 5. Bladder cancer
- 6. Others (e.g., lymphomas, sarcomas)
- 🔔 Key Toxicity
  - Cardiotoxicity:
  - Dose-dependent.
  - Related to free radical formation.
  - Risk of cardiotoxicty
  - Cumulative dose limits should be observed.

## <u>2. Paclitaxel (Taxane Group)</u>

Source:

• Alkaloid from Pacific and European yew trees (صنوبريات)

Mechanism of Action:

- Mitotic spindle poison  $\rightarrow$  inhibits mitosis and cell division

Pharmacokinetics:

- Metabolized by CYP enzymes
- ~80% excreted in feces
- Dose reduction in hepatic impairment

Therapeutic Uses:

- Ovarian cancer
- Advanced breast cancer
- Prostate cancer
- Bladder cancer
- Others

Adverse Effects:

- 1. Dose-limiting:
- Nausea, vomiting
- Myelosuppression
- Peripheral sensory neuropathy
- Hypotension and arrhythmias
- 2. Hypersensitivity reactions (~5%)  $\rightarrow$  Requires premedication with:
- Dexamethasone
- Diphenhydramine (H1 blocker)
- H2 blocker
- 3. Albumin-bound formulation (for breast cancer):
- Less hypersensitivity risk
- No premedication required
- Milder myelosuppression
- Reversible neurotoxicity

## <u>3. Ixabepilone</u>

Class:

• Microtubule inhibitor, NOT a taxane

Indication:

Metastatic breast cancer

Adverse Effects:

- Hypersensitivity reactions
- Myelosuppression
- Neurotoxicity (especially peripheral neuropathy)

## 🔷 <u>4. Bevacizumab</u>

Class:

- Anti-angiogenesis agent
- Humanized monoclonal antibody targeting VEGF-A

### Mechanism of Action:

• Binds VEGF-A  $\rightarrow$  prevents interaction with VEGF receptor  $\rightarrow$  inhibits new blood vessel formation (angiogenesis)

Use:

• Adjunct in tumors that require high vascular supply (e.g., metastatic cancers including breast cancer)

Toxicity:

- Hypertension
- Arterial thromboembolism (TIA, MI, stroke, angina)
- Impaired wound healing
- GI perforation
- Proteinuria

### <u>5. Trastuzumab (Herceptin)</u>

Class:

• Recobinant Humanized monoclonal antibody against HER-2/neu receptor

Mechanism of Action:

- Binds HER-2 receptor  $\rightarrow$  blocks ligand binding to the receptor
- Downregulates receptor expression

#### Use:

• Metastatic breast cancer in HER-2 positive patients (Used in HER-2 overexpressing tumors)

Adverse Effect:

• Cardiotoxicity  $\rightarrow \downarrow$  Left ventricular ejection fraction (LVEF)



### Mainly Used Agents:

- Platinum analogs: Cisplatin, Carboplatin
- Alkylating agents: Cyclophosphamide, Altretamine
- Taxanes: Paclitaxel
- Topoisomerase inhibitors: Topotecan
- Anthracyclines: Doxorubicin

## Platinum Analogs (Cisplatin & Carboplatin)

- Mechanism of Action
  - Act like alkylating agents.
  - Form DNA intra- and inter-strand cross-links  $\rightarrow$  inhibit DNA synthesis and function.
  - Cell cycle non-specific (kill in all phases).

Therapeutic Uses of cisplatin :

- Ovarian cancer
- Breast, testicular, bladder cancers, and others

1 Toxicity:

Carboplatin

Severe nausea/vomitingMilder nausea/vomitingNephrotoxicityLess nephrotoxicOtotoxicityLess ototoxic

Peripheral neuropathy Less neurotoxicity

Dose-limiting toxicity = myelosuppression

P Note:

· Dose reduction needed in renal dysfunction bcz it is elemenating in kidny

### 🜿 Camptothecins (e.g. Topotecan)

derived from a tree grown in China.

Cisplatin

- Mechanism of Action
  - Inhibits topoisomerase I  $\rightarrow$  prevents re-ligation of single-strand DNA breaks  $\rightarrow$  DNA damage  $\rightarrow$  cell death.

🎯 Use

• Second-line therapy for advanced ovarian cancer after platinum-based chemo.

1 Toxicities

- 1. Nausea and vomiting
- 2. Myelosuppression
- 3. Dose reduction needed in renal impairment

### \delta <u>Altretamine</u>

- 🔬 Mechanism of Action
  - Alkylating agent
  - Forms DNA cross-links  $\rightarrow$  inhibits DNA synthesis and function.
- 1 Toxicities
  - 1. Nausea and vomiting
  - 2. Myelosuppression
  - 3. Peripheral neuropathy
  - 4. Flu-like syndrome

#### Prostate Cancer Treatment

V Primary Goal:

Reduce or eliminate testosterone (which stimulates prostate cancer growth)

Main Approaches:

- 1. Surgical castration (orchiectomy)
- 2. Hormonal therapy (chemical castration):
- GnRH analogs (e.g., leuprolide)
- Antiandrogens (e.g., flutamide, bicalutamide)
- 5α-reductase inhibitors (e.g., finasteride, dutasteride)

(discussed in previous sections)

### Mitoxantrone

Class:

- Anthracenedione (related to anthracyclines)
- Chemotherapeutic antibiotic

Mechanism of Action:

- 1. Intercalates into DNA  $\rightarrow$  causes single- and double-stranded breaks
- 2. Inhibits topoisomerase II  $\rightarrow$  suppresses DNA repair and replication

Used for :

· Advanced, hormone-refractory (castration-resistant) prostate cancer

Toxicity Profile:

- 1. Myelosuppression (especially leukopenia)  $\rightarrow$  Dose-limiting toxicity
- 2. Thrombocytopenia
- 3. Nausea and vomiting
- 4. Alopecia
- 5. Mucositis
- 6. Bluish discoloration of:
- Fingernails
- Sclera
- Urine

(typically 1-2 days post-administration)

**Prugs for Testicular Cancer** 

📄 Main Drugs

1. Cisplatin. 2. Etoposide. 3. Bleomycin 4. Ifosfamide (similar to cyclophosphamide)

## 🔬 1. <u>Etoposide</u>

Source:

• Semisynthetic derivative of podophyllotoxin (from mayapple root).

### Mechanism of Action:

- Inhibits topoisomerase II.
- Forms a ternary complex (drug + DNA + enzyme)  $\rightarrow$  DNA strand breaks  $\rightarrow$  apoptosis.

🍤 Formulation:

- IV and oral available.
- Dose adjustment in renal dysfunction.

## 1 Toxicities:

- 1. Nausea & vomiting
- 2. Hypotension
- 3. Myelosuppression
- 4. Alopecia

## 🖉 2. <u>Bleomycin</u>

Action:

• Antitumor antibiotic.

- Binds DNA  $\rightarrow$  generates free radicals (via iron-binding)  $\rightarrow$  causes single & double strand breaks  $\rightarrow$  inhibits DNA synthesis.

Cell-cycle specific:

• G2 phase arrest.

🖉 Clinical Use:

- Testicular cancer
- Squamous cell carcinoma of cervix & vulva
- 1 Renal dysfunction requires dose adjustment

Ose-Limiting Toxicity: Pulmonary toxicity

- Pneumonitis, dry crackles, dyspnea, infiltrates.
- ↑ Risk in:
- Age > 70
- Dose > 400 units
- Underlying lung disease
- Prior chest radiation

Other Toxicities:

- 1. Allergic reactions
- 2. Fever
- 3. Hypotension
- 4. Dermatotoxicity
- 5. Alopecia
- 6. Mucositis

/ 3. Cisplatin

راجع معلوماته ضمن أدوية سرطان المبيض، لأن الاستخدام والمضاعفات متشابهة.

- Cell cycle–nonspecific
- Binds DNA, forming cross-links
- Renal excretion  $\rightarrow$  dose adjust in renal dysfunction

# 🖋 4. <u>Ifosfamide</u>

- Mechanism: Like cyclophosphamide. -so... – alkylates DNA  $\rightarrow$  cross-links  $\rightarrow$  cell death.
- Used in germ cell tumors, including testicular cancer.
- Requires co-administration of Mesna to prevent hemorrhagic cystitis.
- Toxicities: Hemorrhagic cystitis, neurotoxicity, nephrotoxicity, myelosuppression.

0	Bone marrow toxicity (myelosuppression).			
2	Impaired wound healing.	0	Specific ADBs	
3	Loss of hair (alopecia).	C		
(f)	Damage to GI epithelium (including oral mucous membranes).		Specific for	
(5)	Hepatotoxicity		each drug	
6	Sterility.			
()	Teratogenicity & Carcinogenicity – because many cytotoxic drugs are			
	mutagens.			